China
Africa
Explore chapters and articles related to this topic
Tumor resection
Published in A Peyman MD Gholam, A Meffert MD Stephen, D Conway MD FACS Mandi, Chiasson Trisha, Vitreoretinal Surgical Techniques, 2019
In another study, the National Cancer Institute is evaluating hyperthermic isolated hepatic perfusion.57 Temporary separation of the hepatic circulation is followed by hepatic administration of high-dose melphalan. The circulation is then reestablished followed by temozolomide. This modality allows higher localized administration while lessening systemic complications.
Role of immune checkpoint inhibitors in metastatic uveal melanoma: a single-center retrospective cohort study
Published in Acta Oncologica, 2023
Lize Vanaken, F.J. Sherida H. Woei-A-Jin, Rita Van Ginderdeuren, Christophe M. Deroose, Annouschka Laenen, Guy Missotten, Dietmar R. Thal, Oliver Bechter, Patrick Schöffski, Paul Clement
Treatments were categorized as ICI, other systemic treatments, local treatments or best supportive care (BSC) (i.e., no anti-cancer treatment). Since ICI was introduced in our hospital as treatment for MUM on August 1st, 2010, we refer to the period before this date as the pre-ICI era and the period afterwards as the ICI era. All patients were observed until data cutoff on August 1st, 2022. The category ‘other systemic treatments’ included chemotherapy, tyrosine kinase inhibitors and Tebentafusp. Local treatments included LDT and local therapies such as surgery and external beam radiotherapy for oligometastatic disease. In our center, the selective internal radiation therapy (SIRT) procedure consisted of injection of radioactive 90Yttrium microspheres in the common/right/left hepatic artery or smaller branches (tumoricidal dose >100 Gy). For trans-arterial embolization small particles without chemotherapeutic impregnation were used. High dose melphalan was used for isolated hepatic perfusion. Combination of ipilimulab and nivolumab followed by nivolumab monotherapy was counted as one treatment line unless interrupted by local therapies. Consecutive treatments with different classes of ICI upon disease progression were counted as separate treatment lines.
Prognostic biomarker replication factor C subunit 5 and its correlation with immune infiltrates in acute myeloid leukemia
Published in Hematology, 2022
Wang-jun Li, Dong-wei Wu, Yi-feng Zhou, Chen-wei Zhang, Xiao-wei Liao
Replication factor C (RFC) is a five-subunit complex comprised of RFC1 (140 kDa), RFC2 (40 kDa), RFC3 (38 kDa), RFC4 (37 kDa), and RFC5 (36 kDa) [9], which are highly conserved in all eukaryotes [10–12]. The five subunits have high homology to each other [13]. It has been reported that RFC can load proliferating cell nuclear antigen and DNA polymerase onto a template-primer junction in an ATP-dependent manner [14]. Besides, RFC represents a crucial role in checkpoint control, DNA polymerase switching, and DNA repair [15–17]. As a subunit of RFC, RFC5 is involved in cell cycle regulation, nucleotide excision, DNA double helix damage, and repairing mismatches [18, 19]. A previous study showed significant RFC5 upregulation in prostate cancer compared to normal prostate tissues [20]. In cervical cancer C33A cells, overexpression of SIX1 upregulated the RFC5 expression [21]. Additionally, the elevated RFC5 expression in tumor tissues prior to isolated hepatic perfusion is significantly related to poor prognosis [22]. However, little is known about the connection of RFC5 with AML.
Tebentafusp for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma
Published in Expert Review of Anticancer Therapy, 2022
Lanyi Nora Chen, Richard D. Carvajal
For patients who develop metastatic uveal melanoma, prognosis is poor and median survival is estimated at 12 months [12–16]. A meta-analysis of 29 trials for metastatic uveal melanoma between 2000 and 2016 identified a 1-year overall survival (OS) of 43% regardless of prior treatment [16]. For some patients with oligometastatic liver disease, surgical resection, and other regional approaches such as intra-arterial chemotherapy, hepatic artery chemoembolization, immunoembolization, radioembolization, isolated hepatic perfusion, and percutaneous hepatic perfusion can improve disease control, though careful patient selection is critical and survival benefit is largely unclear [17–24]. Until recently, advances in systemic treatments have not been shown to meaningfully improve survival [13]. Chemotherapeutic agents such as dacarbazine, temozolomide, and cisplatin have not demonstrated significant clinical activity [25]. Unlike its cutaneous counterpart, metastatic uveal melanoma is also largely refractory to immune checkpoint inhibitors. Single-agent checkpoint inhibitors have had disappointing clinical trial results. In one phase II trial, single-agent ipilimumab led to a 1-year OS of 22%, which was the primary endpoint; it did not lead to any partial or complete responses, and median OS was 6.8 months [26]. A phase II trial of single-agent tremelimumab, which had a primary endpoint of progression-free survival (PFS) at 6 months, led to a 9.1% 6-month PFS rate, no responses, and an OS of 12.8 months [27]. A retrospective review of patients treated with PD-1 or PD-L1 blockade yielded an objective response rate (ORR) of 3.6% and median OS of 7.6 months [28].